Khalid O Alfarouk
Overview
Explore the profile of Khalid O Alfarouk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
973
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alhoufie S, Mumena W, Alsharif N, Makhdoom H, Almutawif Y, Alfarouk K, et al.
Infect Drug Resist
. 2023 Aug;
16:5573-5586.
PMID: 37645558
Introduction: The global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) increased the demand for intensive care unit (ICU) services. Mortality and morbidity rates among ICU COVID-19...
2.
Harguindey S, Reshkin S, Alfarouk K
Cancers (Basel)
. 2023 Jan;
15(2).
PMID: 36672490
A century ago, Otto Warburg published that aerobic glycolysis and the respiratory impairment of cells were the prime cause of cancer, a phenomenon that since then has been known as...
3.
Alhoufie S, Alhhazmi A, Mahallawi W, Alfarouk K, Ibrahim N
Healthcare (Basel)
. 2022 Nov;
10(11).
PMID: 36421640
Background: Community-acquired atypical pneumonia is generally a mild and self-limiting infection. Still, it may lead to hospitalization and progressive clinical complications in some cases, particularly among the elderly and individuals...
4.
Alhoufie S, Ibrahim N, Alhhazmi A, Makhdoom H, Ali H, Hemeg H, et al.
Infect Drug Resist
. 2022 Nov;
15:6589-6599.
PMID: 36386419
Background: () infection is relevant to several chronic human diseases, from digestive diseases to renal, metabolic, and cancer diseases. infections and chronic kidney diseases are in increasing, global records; if...
5.
Alhoufie S, Ibrahim N, Alsharif N, Alfarouk K, Makhdoom H, Aljabri K, et al.
Saudi Med J
. 2022 Sep;
43(9):1000-1006.
PMID: 36104051
Objectives: To investigate the seroprevalence of the community-acquired bacterial that causes atypical pneumonia among confirmed severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) patients. Methods: In this cohort study, we retrospectively...
6.
Alhoufie S, Alfarouk K, Makhdoom H, Ibrahim N
J Infect Public Health
. 2022 Jun;
15(7):752-756.
PMID: 35714396
Background: Coinfections with respiratory viruses among SARS CoV-2 patients have been reported by several studies during the current COVID-19 pandemic. Most of these studies designated these coinfections as being hospital-acquired...
7.
Carvalho T, Di Molfetta D, Greco M, Koltai T, Alfarouk K, Reshkin S, et al.
Cancers (Basel)
. 2021 Dec;
13(23).
PMID: 34885243
Currently, the median overall survival of PDAC patients rarely exceeds 1 year and has an overall 5-year survival rate of about 9%. These numbers are anticipated to worsen in the...
8.
Alhoufie S, Alsharif N, Alfarouk K, Ibrahim N, Kheyami A, Aljifri A
J Infect Public Health
. 2021 Oct;
14(11):1567-1570.
PMID: 34627054
The emerging of the COVID-19 pandemic is currently challenging for the public health system globally. Beyond SARS-CoV-2 pathogenicity, co-infections with recycling respiratory pathogens, whether bacterial, viral, or fungal, might increase...
9.
Alfarouk K, Alqahtani S, Alshahrani S, Morgenstern J, Supuran C, Reshkin S
J Enzyme Inhib Med Chem
. 2021 Sep;
36(1):2010-2015.
PMID: 34517737
Tumours reprogram their metabolism to acquire an evolutionary advantage over normal cells. However, not all such metabolic pathways support energy production. An example of these metabolic pathways is the Methylglyoxal...
10.
Alfarouk K, Alhoufie S, B M Ahmed S, Shabana M, Ahmed A, Alqahtani S, et al.
J Xenobiot
. 2021 Jun;
11(2):77-93.
PMID: 34063739
COVID-19, occurring due to SARS-COV-2 infection, is the most recent pandemic disease that has led to three million deaths at the time of writing. A great deal of effort has...